İdiyopatik Anafilaksi

immunoloji alerji ozel 13-3 kapak

Hilal ÜNSALa, Cem AKINb
aHacettepe Üniversitesi Tıp Fakültesi, Çocuk İmmünolojisi ve Alerji Hastalıkları BD, Ankara, TÜRKİYE
bMichigan Üniversitesi Tıp Fakültesi, Alerji ve Klinik İmmünoloji BD, Ann Arbor, Michigan, ABD

Ünsal H, Akın C. İdiyopatik anafilaksi. Akın C, Şekerel BE. editörler. Anafilaksi. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. p.25-33.

ÖZET
Herhangi bir tetikleyici nedenin gösterilemediği anafilaksi, idiyopatik anafilaksi (İA) olarak adlandırılır. İdiyopatik anafilaksi (İA), diğer anafilaksi formlarına benzer semptomları olan hayatı tehdit eden bir hastalıktır. İA çocuk hastalarda gösterilmiş olmasına rağmen erişkinlerde daha sık gözlenir. İA patogenezinde temel mekanizmanın mast hücre degranülasyonu olduğu ve bunun yanında yine atak sırasında T ve B lenfosit ve bazofil hücre aktivasyonu olduğu da gösterilmiştir. İA düşünülen tüm hastalar bir alerji uzmanına yönlendirilmelidir. Anafilaksiye neden olan olası tüm tetikleyiciler ve anafilaksiyi taklit eden hastalıklar tanı konulmadan önce düşünülmeli ve dışlanmalıdır. Egzersiz, ilaç, enfeksiyon ve alkol gibi kofaktörlerin etkisi ile mast hücre bozuklukları göz önünde bulundurulmalıdır. Mast hücre bozuklukları yanlışlıkla İA tanısı alabilir. Klonal mast hücre hastalıklarında anafilaksi genellikle hipotansiyon ile seyreder. Ürtiker ve anjioödem genellikle ataklara eşlik etmez. İA tanısı kapsamlı bir hikaye, fizik muayene, tıbbi kayıtların gözden geçirilmesi ve uygun laboratuvar testleri yapıldıktan sonra konulur. Detaylı alerji öyküsü ve alerji tanı testlerinin açıklayamadığı durumlarda ek bilgi sunabilen moleküler yöntemler çalışılabilir. İA’nın prognozu genellikle uygun tedavi ve hasta eğitimi ile ilişkilidir. Halen İA için standart uzun vadeli bir profilaksi rejimi yoktur. Sık görülen ataklar ile seyreden İA olgularında veya yakın zamanda hayatı tehdit edici seviyede atak geçirmiş hastalarda kombine tedavi (oral kortikosteroid ve antihistaminik) gerekebilir. Tedaviye yanıt vermeyen bazı hastalarda omalizumab kullanımı yarar sağlamıştır.

Anahtar Kelimeler: Anafilaksi; idiyopatik; tanı; mast hücresi; kortikosteroid

Referanslar

  1. Carter MC, Akin C, Castells MC, Scott Ep, Lieberman p. Idiopathic anaphylaxis yardstick: practical recommendations for clinical practice. Annals of Allergy, Asthma & Immunology. 2020;124:16-27. [Crossref]  [PubMed]
  2. Nwaru BI, Dhami S, Sheikh A. Idiopathic anaphylaxis. Current treatment options in allergy. 2017;4:312-9. [Crossref]  [PubMed]  [PMC]
  3. Ditto AM, Harris KE, Krasnick j, Miller MA, patterson R. Idiopathic anaphylaxis: a series of 335 cases. Annals of Allergy, Asthma & Immunology. 1996;77:285-91. [Crossref]  [PubMed]
  4. Alonso MAT, Dominguez jS, Sanchez-Hernandez jj, Frances Cp, Caballer BD. Idiopathic anaphylaxis: a descriptive study of 81 patients in Spain. Annals of Allergy, Asthma & Immunology. 2002;88:313-8. [Crossref]  [PubMed]
  5. Fenny N, grammer LC. Idiopathic anaphylaxis. Immunology and Allergy Clinics. 2015;35:349-62. [Crossref]  [PubMed]
  6. Bilò MB, Martini M, Tontini C, Mohamed oE, Krishna MT. Idiopathic anaphylaxis. Clinical & Experimental Allergy. 2019;49:942-52. [Crossref]  [PubMed]
  7. Patterson R, Hogan MB, Yarnold pR, Harris KE. Idiopathic anaphylaxis: an attempt to estimate the incidence in the united States. Archives of internal medicine. 1995;155:869- 71. [Crossref]  [PubMed]
  8. Pattanaik D, Lieberman p, Lieberman j, pongdee T, Keene AT. The changing face of anaphylaxis in adults and adolescents. Annals of Allergy, Asthma & Immunology. 2018;121: 594-7. [Crossref]  [PubMed]
  9. Gonzalez-Estrada A, Silvers SK, Klein A, zell K, Wang x-F, Lang DM. Epidemiology of anaphylaxis at a tertiary care center: a report of 730 cases. Annals of Allergy, Asthma & Immunology. 2017;118:80-5. [Crossref]  [PubMed]
  10. Wright CD, Longjohn M, Lieberman pL, Lieberman jA. An analysis of anaphylaxis cases at a single pediatric emergency department during a 1-year period. Annals of Allergy, Asthma & Immunology. 2017;118:461-4. [Crossref]  [PubMed]
  11. Greenberger pA. Idiopathic anaphylaxis. Immunology and allergy clinics of North America. 2007;27:273-93. [Crossref]  [PubMed]
  12. Grammer LC, Shaughnessy MA, Harris KE, goolsby C. Lymphocyte subsets and activation markers in patients with acute episodes of idiopathic anaphylaxis. Annals of Allergy, Asthma & Immunology. 2000;85:368-71. [Crossref]  [PubMed]
  13. Howell D, jacobs C, Metz g, et al. Molecular profiling distinguishes patients with active idiopathic anaphylaxis from normal volunteers and reveals novel aspects of disease biology. journal of Allergy and Clinical Immunology. 2009;123:S150. [Crossref]
  14. Tedeschi A, Lorini M, Suli C, Cugno M. Detection of serum histamine-releasing factors in a patient with idiopathic anaphylaxis and multiple drug allergy syndrome. jouRNAL oF INVESTIgATIoNAL ALLERgoLogY AND CLINICAL IMMuNoLogY. 2007;17:122.
  15. Lenchner K, grammer LC. A current review of idiopathic anaphylaxis. Current opinion in allergy and clinical immunology. 2003;3:305-11. [Crossref]  [PubMed]
  16. Ditto AM, Krasnick j, greenberger pA, Kelly Kj, Mcgrath K, patterson R. pediatric idiopathic anaphylaxis: experience with 22 patients. journal of allergy and clinical immunology. 1997;100:320-6. [Crossref]  [PubMed]
  17. Furlong Tj, DeSimonea j, Sicherer SH. peanut and tree nut allergic reactions in restaurants and other food establishments. journal of Allergy and Clinical Immunology. 2001;108:867-70. [Crossref]  [PubMed]
  18. Baker Mg, Saf S, Tsuang A, Nowak-Wegrzyn A. Hidden allergens in food allergy. Annals of Allergy, Asthma & Immunology. 2018;121:285- 92. [Crossref]  [PubMed]
  19. Moneret-Vautrin D, Morisset M, Lemerdy p, Croizier A, Kanny g. Food allergy and IgE sensitization caused by spices: CICBAA data (based on 589 cases of food allergy). Allergie et immunologie. 2002;34:135-40.
  20. Khalili B, Bardana jr Ej, Yunginger jW. psyllium-associated anaphylaxis and death: a case report and review of the literature. Annals of Allergy, Asthma & Immunology. 2003;91:579-84. [Crossref]  [PubMed]
  21. Greenberger pA, Flais Mj. Bee pollen-induced anaphylactic reaction in an unknowingly sensitized subject. Annals of allergy, asthma & immunology. 2001;86:239-42. [Crossref]  [PubMed]
  22. Sánchez-Borges M, Suárez-Chacón R, Capriles-Hulett A, Caballero-Fonseca F. An update on oral anaphylaxis from mite ingestion. Annals of Allergy, Asthma & Immunology. 2005;94:216-21. [Crossref]  [PubMed]
  23. Wölbing F, Fischer j, Köberle M, Kaesler S, Biedermann T. About the role and underlying mechanisms of cofactors in anaphylaxis. Allergy. 2013;68:1085-92. [Crossref]  [PubMed]
  24. Steinke jW, platts-Mills TA, Commins Sp. The alpha-gal story: lessons learned from connecting the dots. journal of Allergy and Clinical Immunology. 2015;135:589-96. [Crossref]  [PubMed]  [PMC]
  25. Tripathi A, Commins Sp, Heymann pW, plattsMills TA. Delayed anaphylaxis to red meat masquerading as idiopathic anaphylaxis. The journal of Allergy and Clinical Immunology: In practice. 2014;2:259-65. [Crossref]  [PubMed]  [PMC]
  26. Stoltz Lp, Cristiano LM, Dowling Ap, Wilson jM, platts-Mills TA, Traister RS. Could chiggers be contributing to the prevalence of galactose-alpha-1, 3-galactose sensitization and mammalian meat allergy? The journal of allergy and clinical immunology. In practice. 2019;7:664. [Crossref]  [PubMed]  [PMC]
  27. Keleş Ş, gündüz M. Alpha gal specific IgE positivity due to tick bites and red meat allergy: the first case report in Turkey. 2019. [Crossref]  [PubMed]
  28. Carter M, Ruiz-Esteves K, Workman L, Lieberman p, platts-Mills T, Metcalfe D. Identification of alpha-gal sensitivity in patients with a diagnosis of idiopathic anaphylaxis. Allergy. 2018;73:1131-4. [Crossref]  [PubMed]  [PMC]
  29. Stoevesandt j, grundmeier N, Trautmann A. gastroesophageal hymenoptera stings add to causes of idiopathic anaphylaxis. Annals of Allergy, Asthma & Immunology. 2012;108:125- 6. [Crossref]  [PubMed]
  30. Gelincik A, özşeker F, Büyüköztürk S, Çolakoğlu B, Dal M, Alper A. Recurrent anaphylaxis due to non-ruptured hepatic hydatid cysts. International archives of allergy and immunology. 2007;143:296-8. [Crossref]  [PubMed]
  31. Choy AC, patterson R, patterson DR, et al. undifferentiated somatoform idiopathic anaphylaxis: nonorganic symptoms mimicking idiopathic anaphylaxis. journal of allergy and clinical immunology. 1995;96:893-900. [Crossref]  [PubMed]
  32. Akin C. Mast cell activation syndromes presenting as anaphylaxis. Immunology and Allergy Clinics. 2015;35:277-85. [Crossref]  [PubMed]
  33. giannetti Mp, Akin C, Castells M. Idiopathic anaphylaxis: a form of mast cell activation syndrome. The journal of Allergy and Clinical Immunology: In practice. 2020;8:1196-201. [Crossref]  [PubMed]
  34. Akin C. Mast cell activation syndromes. journal of Allergy and Clinical Immunology. 2017; 140:349-55. [Crossref]  [PubMed]
  35. Valent p, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. International archives of allergy and immunology. 2012;157:215-25. [Crossref]  [PubMed]  [PMC]
  36. Valent p, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHo classification and novel emerging treatment concepts. Blood, The journal of the American Society of Hematology. 2017;129:1420-7. [Crossref]  [PubMed]  [PMC]
  37. Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood, The journal of the American Society of Hematology. 2007;110:2331-3. [Crossref]  [PubMed]  [PMC]
  38. Carter MC, Desai A, Komarow HD, et al. A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. journal of Allergy and Clinical Immunology. 2018;141:180-8. e183. [Crossref]  [PubMed]  [PMC]
  39. Alvarez-Twose I, gonzalez-de-olano D, Sánchez-Muñoz L, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. International archives of allergy and immunology. 2012;157:275-80. [Crossref]  [PubMed]
  40. Heaps A, Carter S, Selwood C, et al. The utility of the ISAC allergen array in the investigation of idiopathic anaphylaxis. Clinical & Experimental Immunology. 2014;177:483-90. [Crossref]  [PubMed]  [PMC]
  41. Greenberger pA, Lieberman p. Idiopathic anaphylaxis. The journal of Allergy and Clinical Immunology: In practice. 2014;2:243-50. [Crossref]  [PubMed]
  42. Muraro A, Roberts g, Clark A, et al. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy. 2007;62:857- 71. [Crossref]  [PubMed]
  43. Fernandez j, Akin C. Management of idiopathic anaphylaxis: when is bone marrow examination essential? Current Treatment options in Allergy. 2014;1:221-31. [Crossref]
  44. Patterson R, Fitzsimons Ej, Choy AC, Harris KE. Malignant and corticosteroid-dependent idiopathic anaphylaxis: successful responses to ketotifen. Annals of Allergy, Asthma & Immunology. 1997;79:138-44. [Crossref]  [PubMed]
  45. Özdemir ö, Bozkurt HB, Elmas B. omalizumab's role in the treatment of steroid dependent malignant idiopathic anaphylaxis. Turkish Archives of pediatrics/Türk pediatri Arşivi. 2017;52:105. [Crossref]  [PubMed]  [PMC]
  46. Warrier p, Casale TB. omalizumab in idiopathic anaphylaxis. Annals of Allergy, Asthma & Immunology. 2009;102:257- 8. [Crossref]  [PubMed]
  47. Borzutzky A, Morales pS, Mezzano V, Nussbaum S, Burks AW. Induction of remission of idiopathic anaphylaxis with rituximab. journal of Allergy and Clinical Immunology. 2014;134: 981-3. [Crossref]  [PubMed]